- Home
- ADEA vs NNNN Comparison
ADEA vs NNNN Comparison
Compare ADEA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- NNNN
- Stock Information
- Founded
- ADEA 1990
- NNNN 2021
- Country
- ADEA United States
- NNNN Germany
- Employees
- ADEA N/A
- NNNN N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ADEA Technology
- NNNN Health Care
- Exchange
- ADEA Nasdaq
- NNNN Nasdaq
- Market Cap
- ADEA 1.8B
- NNNN 2.2B
- IPO Year
- ADEA N/A
- NNNN 2025
- Fundamental
- Price
- ADEA $17.29
- NNNN $32.16
- Analyst Decision
- ADEA Strong Buy
- NNNN
- Analyst Count
- ADEA 4
- NNNN 0
- Target Price
- ADEA $19.50
- NNNN N/A
- AVG Volume (30 Days)
- ADEA 554.0K
- NNNN 70.5K
- Earning Date
- ADEA 11-06-2025
- NNNN 10-23-2025
- Dividend Yield
- ADEA 1.16%
- NNNN N/A
- EPS Growth
- ADEA 80.44
- NNNN N/A
- EPS
- ADEA 0.74
- NNNN 0.06
- Revenue
- ADEA $378,674,000.00
- NNNN $8,185,146.00
- Revenue This Year
- ADEA $9.49
- NNNN N/A
- Revenue Next Year
- ADEA $4.94
- NNNN N/A
- P/E Ratio
- ADEA $23.37
- NNNN $594.87
- Revenue Growth
- ADEA 5.47
- NNNN 21.95
- 52 Week Low
- ADEA $10.59
- NNNN $5.18
- 52 Week High
- ADEA $17.84
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- ADEA 72.43
- NNNN N/A
- Support Level
- ADEA $16.36
- NNNN N/A
- Resistance Level
- ADEA $16.98
- NNNN N/A
- Average True Range (ATR)
- ADEA 0.51
- NNNN 0.00
- MACD
- ADEA 0.04
- NNNN 0.00
- Stochastic Oscillator
- ADEA 79.17
- NNNN 0.00
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.